{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:30:53Z","timestamp":1790195453488,"version":"4.1.0"},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:p>Recently, a new disease of lymphocyte homeostasis caused by somatic mosaicism for the <jats:italic toggle=\"yes\">RAS<\/jats:italic> mutation has been discovered (known as RALD, RAS-associated leukoproliferative disorder). Since few cases have been reported in literature, the prognosis and standard treatment for autoimmune diseases associated with RALD remain poorly understood. Standard rituximab therapy (375\u2009mg\/m<jats:sup>2<\/jats:sup> for 4\u2009wk) is effective in patients with autoimmune diseases, but early recurrences are common. We highlight the potential for monthly administration of rituximab in a patient with autoimmune thrombocytopenia and hemolytic anemia associated with RALD. RALD was diagnosed in an 11-year-old girl following a 9-year history of severe hepatosplenomegaly and autoimmune cytopenias. Genetic analyses confirmed somatic mosaicism for the G13C KRAS mutation without an autoimmune lymphoproliferative syndrome\u2013related gene mutation. Rituximab therapy was used because of the refractory character of the autoimmune cytopenias which failed to respond to steroids and other immunosuppressive agents. Her treatment consisted of weekly infusions of rituximab for 4 weeks followed by monthly rituximab for 11 months. She maintained her response in hematologic parameters for 2 years after monthly rituximab was ceased and her scores representing quality of life were improved. Rituximab could improve clinical responses and quality of life of the patients with RALD.<\/jats:p>","DOI":"10.1097\/mph.0000000000001276","type":"journal-article","created":{"date-parts":[[2018,8,5]],"date-time":"2018-08-05T23:20:16Z","timestamp":1533511216000},"page":"e516-e518","source":"Crossref","is-referenced-by-count":13,"title":["Weekly Rituximab Followed by Monthly Rituximab Treatment for Autoimmune Disease Associated With RAS-associated Autoimmune Leukoproliferative Disease"],"prefix":"10.1097","volume":"40","author":[{"given":"Hidemi","family":"Toyoda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Deguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shotaro","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Kihira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Hori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Komada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Hirayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230918","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood-2014-11-567917","article-title":"JMML and RALD (Ras-associated autoimmune leukoproliferative disorder): common genetic etiology yet clinically distinct entities","volume":"125","author":"Calvo","year":"2015","journal-title":"Blood"},{"key":"R2-20230918","doi-asserted-by":"crossref","first-page":"8953","DOI":"10.1073\/pnas.0702975104","article-title":"NRAS mutation causes a human autoimmune lymphoproliferative syndrome","volume":"104","author":"Oliveira","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"R3-20230918","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1182\/blood-2010-08-301515","article-title":"Autoimmune lymphoproliferative syndrome-like disease with somatic KRAS mutation","volume":"117","author":"Takagi","year":"2011","journal-title":"Blood"},{"key":"R4-20230918","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1182\/blood-2010-07-295501","article-title":"Somatic KRAS mutations associated with a human nonmalignant syndrome of autoimmunity and abnormal leukocyte homeostasis","volume":"117","author":"Niemela","year":"2011","journal-title":"Blood"},{"key":"R5-20230918","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1182\/blood-2014-01-548958","article-title":"RAS-associated lymphoproliferative disease evolves into severe juvenile myelo-monocytic leukemia","volume":"123","author":"Lanzarotti","year":"2014","journal-title":"Blood"},{"key":"R6-20230918","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1007\/s10875-015-0163-3","article-title":"Somatic mosaicism for a NRAS mutation associates with disparate clinical features in RAS-associated leukoproliferative disease: a report of two cases","volume":"35","author":"Shiota","year":"2015","journal-title":"J Clin Immunol"},{"key":"R7-20230918","doi-asserted-by":"crossref","first-page":"e245","DOI":"10.1038\/bcj.2014.65","article-title":"Monthly administration of rituximab is useful for patients with ocular adnexal mucosa-associated lymphoid tissue lymphoma","volume":"4","author":"Mino","year":"2014","journal-title":"Blood Cancer J"},{"key":"R8-20230918","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.3324\/haematol.2010.026104","article-title":"Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study","volume":"95","author":"Kim","year":"2010","journal-title":"Haematologica"},{"key":"R9-20230918","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1038\/leu.2013.82","article-title":"Autoimmunity and persistent RAS-mutated clones long after the spontaneous regression of JMML","volume":"27","author":"Takagi","year":"2013","journal-title":"Leukemia"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00043426-201811000-00023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T04:06:57Z","timestamp":1695010017000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00043426-201811000-00023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":9,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000001276","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]}}}